Nucala 100 mg solution for injection in pre-filled pen

DRUG3 trials

Sponsors

Hospices Civils De Lyon, Amsterdam UMC, Glaxosmithkline Research & Development Limited

Conditions

AsthmaChronic rhinosinusitis with nasal polyps (CRSwNP)severe asthma

Phase 4

Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE

CompletedCTIS2022-501029-19-00

Hospices Civils De LyonAsthma

Start: 2022-12-13End: 2025-03-27Target: 130Updated: 2024-01-15

A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma.

Active, not recruitingCTIS2023-509026-21-00

Glaxosmithkline Research & Development Limitedsevere asthma

Start: 2024-06-03Target: 170Updated: 2025-12-10

Biomarkers for the prediction of individual CRSwNP patients' responses to mepolizumab

RecruitingCTIS2023-508069-34-01

Amsterdam UMCChronic rhinosinusitis with nasal polyps (CRSwNP)

Start: 2024-08-05Target: 70Updated: 2024-06-03